Eli Lilly and Company· @EliLillyandCo · X·· 10 小时前AI 评分42
AI 导读
肥胖会升高2型糖尿病和心血管疾病的风险。一项事后分析显示，我们的口服减肥药与这两种疾病预测风险的降低相关，且在所有剂量下均观察到风险降低。阅读更多：https://go.lilly.com/9sq6fd
正文
Obesity raises the risk of type 2 diabetes and cardiovascular disease. A post-hoc analysis showed our oral obesity medicine was associated with reductions in the predicted risk of both conditions, with reductions seen across all doses. Read more: https://go.lilly.com/9sq6fd
来源：Eli Lilly and Company · x.com